Form 4: Werewolf Therapeutics Director Michael B. Atkins Acquires Stock Options

Director Michael B. Atkins of Werewolf Therapeutics, Inc. reports acquisition of stock options on May 24, 2024.

Summary

• Michael B. Atkins, a director of Werewolf Therapeutics, Inc. (HOWL), reported a transaction on May 24, 2024.
• Atkins acquired stock options to purchase 6,723 shares of common stock at an exercise price of $4.88.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service as a director.
• Following the transaction, Atkins directly owns 6,723 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of options by a director is mildly positive, suggesting confidence, but not significantly impactful.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by a director of Werewolf Therapeutics.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates